Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -9.89% is 117% below its 5-year average of 57.03%, near the low end of its 5-year range (-12.24%–100.00%).
122.20% below its 12-month average of 44.55%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 22.26%.
GROSS MARGIN
-9.89%
GROSS MARGIN AVG TTM
44.55%
GROSS MARGIN AVG 3Y
46.83%
GROSS MARGIN AVG 5Y
57.03%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-122.20%
CURRENT VS 3Y AVG
-121.12%
CURRENT VS 5Y AVG
-117.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-123.90%
vs the sector median at left
P3 Health Partners Inc.
Market Cap
$18.15M
Gross Margin
-9.89%
TTM Avg
44.55%
3Y Avg
46.83%
5Y Avg
57.03%
Market Cap
$18.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$18.65M
Gross Margin
43.54%
TTM Avg
69.65%
3Y Avg
34.83%
5Y Avg
-433.64%
Market Cap
$17.39M
Gross Margin
10.27%
TTM Avg
10.01%
3Y Avg
10.00%
5Y Avg
11.56%
Market Cap
$17.31M
Gross Margin
-334.26%
TTM Avg
-117.13%
3Y Avg
-347.18%
5Y Avg
-222.70%
Market Cap
$19.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$16.84M
Gross Margin
0.00%
TTM Avg
-52.16%
3Y Avg
-139.89%
5Y Avg
-776.52%
Market Cap
$16.82M
Gross Margin
72.24%
TTM Avg
86.12%
3Y Avg
93.06%
5Y Avg
-220.71%
Market Cap
$16.74M
Gross Margin
99.63%
TTM Avg
49.76%
3Y Avg
72.18%
5Y Avg
92.05%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| P3 Health Partners Inc. (PIII) | $18.15M | -9.89% | 44.55% | 46.83% | 57.03% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | 43.54% | 69.65% | 34.83% | -433.64% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | 10.27% | 10.01% | 10.00% | 11.56% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -334.26% | -117.13% | -347.18% | -222.70% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | 0.00% | -52.16% | -139.89% | -776.52% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | 72.24% | 86.12% | 93.06% | -220.71% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | 99.63% | 49.76% | 72.18% | 92.05% |
| PAVmed Inc. (PAVM)vs › | $16.72M | -354.93% | -228.26% | -369.25% | -249.00% |
Gross Margin
-9.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 22.26% |
| 2026-03-31 | 7.58% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | -7.11% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | -1.55% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 3.69% |
| 2024-03-31 | -3.89% |
| 2023-12-31 | -12.24% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | -2.63% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | -8.48% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | -4.48% |
| 2020-09-30 | 1.42% |
| 2020-06-30 | 9.49% |
| 2020-03-31 | -0.44% |
